Holen Sie sich die Stockscreener-App
0.9317
2.21%
-0.0211
Handel nachbörslich:
.98
0.0483
+5.18%
Schlusskurs vom Vortag:
$0.9528
Offen:
$0.97
24-Stunden-Volumen:
286.81K
Relative Volume:
1.80
Marktkapitalisierung:
$20.35M
Einnahmen:
$950.10K
Nettoeinkommen (Verlust:
$-16.69M
KGV:
-0.9705
EPS:
-0.96
Netto-Cashflow:
$-15.16M
1W Leistung:
-20.03%
1M Leistung:
-28.33%
6M Leistung:
-26.64%
1J Leistung:
-3.44%
1-Tages-Spanne:
$0.91
$0.97
1-Wochen-Bereich:
$0.91
$1.15
52-Wochen-Spanne:
$0.734
$2.40
Femasys Inc Stock (FEMY) Company Profile
Vergleichen Sie FEMY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| FEMY | 0.9317 | 20.35M | 950.10K | -16.69M | -15.16M | -0.96 |
| ISRG | 531.64 | 190.09B | 7.87B | 2.24B | 586.00M | 4.25 |
| BDX | 224.10 | 65.14B | 20.18B | 1.73B | 3.07B | 5.51 |
| ALC | 85.81 | 42.44B | 9.76B | 1.16B | 665.00M | 0.72 |
| RMD | 239.42 | 34.99B | 4.81B | 1.11B | 1.35B | 6.16 |
| WST | 307.21 | 22.29B | 2.88B | 499.60M | 321.60M | 7.41 |
Femasys Inc Aktie (FEMY) Neueste Nachrichten
Femasys Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Femasys Inc. (FEMY) Quarterly 10-Q Report - Quartzy
Femasys Inc. (FEMY) Reports Q3 Loss, Tops Revenue Estimates - MSN
Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update - The Manila Times
Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides - The Bakersfield Californian
Femasys Sales Surge 127% as Boston IVF Partnership, FDA Clearance Fuel Growth | FEMY Stock News - StockTitan
Femasys to Exhibit at the Annual AAGL 2024 Global Conference - GlobeNewswire
FEMYFemasys Inc. Latest Stock News & Market Updates - StockTitan
Femasys secures new patent for FemBloc birth control By Investing.com - Investing.com South Africa
Femasys issued U.S. patent covering FemBloc device - MSN
Femasys Announces Issued U.S. Patent Covering FemBloc® Device for Female Permanent Birth Control - GlobeNewswire
Femasys secures new patent for FemBloc birth control - Investing.com
The 10 Best Booths from ASRM 2022 - Exhibitor Online
Femasys (NASDAQ:FEMY) Has Debt But No Earnings; Should You Worry? - Simply Wall St
Femasys Announces Partnership with Boston IVF, Prominent Network of Fertility Centers, to Offer FemaSeed - GlobeNewswire
Femasys Advances in Women’s Health Innovation - TipRanks
Femasys to Exhibit at ASRM 2024 and Participate in the Congress’ KEEPR Education Program - GlobeNewswire
Femasys to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit - The Manila Times
Femasys Receives Second Order from Spain Partners After - GlobeNewswire
Femasys Receives Second Order from Spain Partners After Successfully Completing Commercial FemaSeed® Infertility Treatments - StockTitan
Femasys Inc (FEMY-Q) QuotePress Release - The Globe and Mail
Femasys announes infertility clinic customers from coast to coast - TipRanks
Femasys Announces Infertility Clinic Customers from Coast to Coast - GlobeNewswire
H.C. Wainwright maintains Buy rating on Femasys on secureing strategic Spain distribution - Investing.com India
Femasys Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga
Femasys secures distribution partnerships for commercialization of FemaSeed - TipRanks
Femasys Secures Strategic Distribution Partnerships for - GlobeNewswire
Femasys Secures Strategic Distribution Partnerships for Commercialization of FemaSeed® for over $1.3M in Spanish Market - StockTitan
Femasys Stock Rises After FDA Clearance for FemChec Diagnostic Device - Yahoo Finance
Items Tagged with 'Femchec' - BioWorld Online
Femasys gains FDA clearance for new diagnostic tool FemChec - Investing.com India
Femasys Femchec receives FDA clearance - BioWorld Online
Femasys gains FDA clearance for new diagnostic tool FemChec By Investing.com - Investing.com UK
Femasys Inc. Receives U.S. FDA Clearance to Market - GlobeNewswire
Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check - StockTitan
FDA clears Femasys’ FemChec diagnostic device - Mass Device
Femasys to Exhibit at The Canadian Fertility and Andrology Society’s 70th Annual Meeting - GlobeNewswire
Femasys Shares Rise on CE Mark & Canada Approval for FemVue MINI - MSN
Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
Femasys Inc (FEMY)’s stock price range in the last year - US Post News
Stocks of Femasys Inc (FEMY) are poised to climb above their peers - SETE News
Femasys Releases Updated Corporate Presentation Online - TipRanks
Femasys Inc (FEMY) Stock: Uncovering a 52-Week Range and Trading Volume - The InvestChronicle
Finanzdaten der Femasys Inc-Aktie (FEMY)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.70%
3.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):